Welcome to our dedicated page for Avalon Globocare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalon GloboCare Corp. (NASDAQ: ALBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents. These filings describe Avalon as a commercial‑stage company focused on precision diagnostic consumer products, cellular therapy intellectual property, generative AI publishing and software, and commercial real estate operations. Through its SEC reports, Avalon details material events such as acquisitions, financing arrangements, Nasdaq listing matters, and progress on its proposed merger with YOOV Group Holding Limited.
In recent Form 8‑K filings, Avalon has reported the acquisition of RPM Interactive, Inc. through its subsidiary Avalon Quantum AI, LLC, adding a generative AI powered SaaS platform for automated short‑form video creation. Other 8‑K and 8‑K/A filings outline senior secured promissory notes, bridge notes, waivers and amendments, unregistered sales of equity securities, and changes to preferred stock designations, including Series C and Series E preferred stock. Filings also document Nasdaq correspondence regarding compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b) and the company’s steps to address those requirements.
SEC filings further describe Avalon’s Agreement and Plan of Merger with YOOV Group Holding Limited and the related Registration Statement on Form S‑4, which contains a preliminary proxy statement/prospectus. These documents explain the structure of the proposed merger, the conditions to closing, and the anticipated focus on Artificial Intelligence‑as‑a‑Service (AIaaS) solutions following completion. Additional disclosures cover the company’s share issuances, beneficial ownership limitations, and updates on outstanding notes and conversion terms.
On Stock Titan, users can review Avalon’s 8‑K, 8‑K/A, 10‑K, and other SEC filings, while AI‑powered tools help summarize complex sections, highlight key terms, and surface information on topics such as financing, preferred stock features, Nasdaq listing status, and merger‑related disclosures. This makes it easier to understand how Avalon’s precision diagnostics, cellular therapy IP, AI software assets, and capital structure are reflected in its official regulatory record.
Avalon GloboCare Corp. filed an amended current report to clarify details of a financing agreement, a senior secured promissory note, and related preferred stock terms.
The company agreed to sell 141,643 shares of common stock for $500,000, or $3.53 per share, to York Sun Investment Holding Limited under a securities purchase agreement. It also entered into a waiver with Mast Hill Fund, L.P. under a $2,845,000 senior secured promissory note, under which the holder waived potential cash penalties tied to a prior issuance of Series C preferred stock but retained dilutive adjustment rights, subject to a $1.00 per-share floor price.
Based on principal, accrued, and estimated future interest, the report states that, at the floor price, the note could be converted into approximately 2,942,041 common shares, subject to a 4.99% beneficial ownership limit. Separately, the Series C preferred stock designation was amended to reduce its beneficial ownership limit from 19.99% to 4.99%, further constraining how much any holder can own through conversion.
Avalon GloboCare Corp. filed a current report describing a planned product launch. The company announced that it intends to begin selling its KetoAir™ breathalyzer device in the United Kingdom starting on September 1, 2025. This step represents an international rollout of the KetoAir™ product beyond existing markets. The announcement was made through a press release that is included as an exhibit and is referenced for further details on the planned UK introduction.
Avalon GloboCare Corp. (ALBT) reported continued operating losses and significant balance sheet activity in the six months ended June 30, 2025. The company recorded recurring net losses of approximately $15.94 million for the six-month period and generated negative operating cash flow of about $3.03 million. During Q1 2025 Avalon completed the redemption of its 40% equity interest in Lab Services MSO for aggregate cash of $1.745 million and the surrender of Series B preferred stock (carrying value $11.0 million), recognizing an increase to additional paid-in capital of $2.3487 million. The company recorded a $9.0766 million loss on extinguishment of debt related to modification/waiver of the June 2024 convertible note financing. Derivative liabilities declined, producing a fair value gain of $446,816 for the six months. The company wrote off and reserved for credit losses ($1.65 million) and reported material warrant and convertible instruments, including the June 2024 convertible note (principal $2.845 million). Avalon’s laboratory services segment ceased upon the Lab Services MSO redemption; the real property segment remains operational.
Avalon GloboCare Corp. issued 221,000 shares of unregistered common stock to a noteholder upon partial conversions of an outstanding promissory note between July 30, 2025 and August 6, 2025. After these issuances the company reported 3,690,109 shares outstanding as of August 6, 2025. The filing states the shares were not registered under the Securities Act and were offered in reliance on the Section 4(a)(2) exemption.
The disclosure provides the exact share amount and updated share count but contains no details on the promissory note balance converted, the conversion price, or any cash impacts. The information is factual and narrow in scope, limited to the share issuance and the registration exemption relied upon.
Avalon GloboCare Corp. (Nasdaq: ALBT) filed a Form 8-K dated 28 Jul 2025 to disclose that its wholly-owned subsidiary, Q&A Distribution, LLC, has entered a distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device. The filing is made under Item 7.01 (Reg FD) and includes the related press release as Exhibit 99.1.
No financial terms, volume commitments or revenue projections were provided. Management expressly states the information is furnished, not filed, thereby avoiding automatic incorporation into other SEC documents. While the agreement could broaden ALBT’s presence in the metabolic health diagnostics market, investors have insufficient data to quantify potential sales or profitability impact. No other material events, financial statements, or pro-forma data accompany this report.